PD-1/PD-L1封锁恢复了瘤诱导的COVID-19疫苗的直接性
Xiangyu Chen1, Yao Lin2, Shuai Yue3
1School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
Vaccine
|July 3, 2023
概括
癌症患者已经降低了COVID-19疫苗的有效性. PD-1/PD-L1免疫检查点阻塞疗法可以通过提高T细胞活性来恢复疫苗反应,独立于抗瘤效应.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 疫苗学 疫苗学 疫苗学
背景情况:
- COVID-19疫苗对于大流行控制至关重要.
- 癌症患者显示COVID-19疫苗的有效性降低.
- PD-1/PD-L1免疫检查点阻塞 (ICB) 疗法在治疗各种癌症方面表现有前途.
研究的目的:
- 研究PD-1/PD-L1 ICB治疗对癌症患者COVID-19疫苗有效性的影响.
- 探索疫苗反应中任何观察到的变化背后的机制.
主要方法:
- 使用了临床前癌症模型.
- 根据PD-1/PD-L1 ICB治疗的存在和缺乏,评估了COVID-19疫苗的反应.
- 分析了免疫细胞群,特别是毛囊辅助T细胞和生殖中心反应.
主要成果:
- 在临床前模型中,PD-1/PD-L1 ICB疗法在很大程度上逆转了被抑制的COVID-19疫苗反应.
- 恢复疫苗的有效性是独立于ICB治疗的抗瘤作用.
- 从机制上讲,恢复的疫苗反应与卵泡辅助T细胞和生殖中心活动的增加有关.
结论:
- PD-1/PD-L1阻塞可以使癌症患者的COVID-19疫苗反应正常化.
- 这种疫苗反应的正常化是无论治疗的抗瘤疗效如何实现的.
- 这些发现突出了提高免疫功能受损的癌症人群疫苗疗效的潜在策略.
相关概念视频
Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
Cancer Vaccines
428
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
428


